These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17053985)

  • 21. Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.
    Rohatagi S; Zahir H; Moberly JB; Truitt KE; Inaba S; Shimozato T; Carrothers TJ
    J Clin Pharmacol; 2009 Jan; 49(1):50-62. PubMed ID: 18948412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
    Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ
    Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.
    Sharma A; Jusko WJ
    Br J Clin Pharmacol; 1998 Mar; 45(3):229-39. PubMed ID: 9517366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development.
    Heinzen EL; Pollack GM
    Brain Res; 2004 Oct; 1023(2):175-84. PubMed ID: 15374743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.
    Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing statistical methods for quantifying drug sensitivity based on in vitro dose-response assays.
    Huang S; Pang L
    Assay Drug Dev Technol; 2012 Feb; 10(1):88-96. PubMed ID: 22066911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis of rate and extent of tolerance of biomarkers: application to nicotinic acid-induced changes in non-esterified fatty acids in rats.
    Ahlström C; Peletier LA; Gabrielsson J
    Eur J Pharm Sci; 2011 Oct; 44(3):250-64. PubMed ID: 21856416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of chronic ethanol administration on disposition of ethanol and its metabolites in rat.
    Kozawa S; Yukawa N; Liu J; Shimamoto A; Kakizaki E; Fujimiya T
    Alcohol; 2007 Mar; 41(2):87-93. PubMed ID: 17517325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers.
    Sharma A; Slugg PH; Hammett JL; Jusko WJ
    J Clin Pharmacol; 1998 Dec; 38(12):1116-21. PubMed ID: 11301563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theoretical basis for the identification of allelic variants that encode drug efficacy and toxicity.
    Lin M; Wu R
    Genetics; 2005 Jun; 170(2):919-28. PubMed ID: 15802521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
    Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
    Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
    Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH;
    Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat.
    Giraudel JM; Diquelou A; Laroute V; Lees P; Toutain PL
    Br J Pharmacol; 2005 Nov; 146(5):642-53. PubMed ID: 16113689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.
    Ikawa K; Kikuchi E; Kikuchi J; Nishimura M; Derendorf H; Morikawa N
    J Clin Pharm Ther; 2014 Aug; 39(4):411-7. PubMed ID: 24661290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat.
    Mandema JW; Wada DR
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1185-94. PubMed ID: 8531080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.